Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 303, Issue 5, 2012, Pages

  Brinkman, Adam S ^a,b   Murali, Sangita G ^b   Hitt, Stacy ^b   Solverson, Patrick M ^b   Holst, Jens J ^c   Ney, Denise M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Insulin like growth factor binding protein 5; Insulin like growth factor I; Intestinal adaptation; Proglucagon; Short bowel syndrome

Indexed keywords

EPIDERMAL GROWTH FACTOR; GLUCAGON LIKE PEPTIDE 2; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CONTROLLED STUDY; INTESTINAL FAILURE; INTESTINE RESECTION; JEJUNOILEOSTOMY; MALE; NONHUMAN; NUTRIENT; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SHORT BOWEL SYNDROME; WEIGHT GAIN;

ANIMALS; DISEASE MODELS, ANIMAL; ENTERAL NUTRITION; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTESTINE, SMALL; MALE; MITOTIC INDEX; PARENTERAL NUTRITION; PROGLUCAGON; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SHORT BOWEL SYNDROME;

EID: 84865741799     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00184.2012     Document Type: Article

References (60)

1. Akiba Y, Mizumori M, Guth PH, Engel E, Kaunitz JD. Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol 293: G1223-G1233, 2007.
2. Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factorbinding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 395: 1-19, 2006.
3. Buchman AL. Etiology and initial management of short bowel syndrome. Gastroenterology 130: S5-S15, 2006.
4. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 16: 962-973, 2010.
5. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology 124: 1111-1134, 2003.
6. Burrin DG, Stoll B, Guan X, Cui L, Chang X, Holst JJ. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 146: 22-32, 2005.
7. Caddy G, Johnston C, Ardill J, Pogue K, Collins J, Gardiner K, Watson P. Distribution of glucagon-like peptide-2 in normal colonic tissue. Scand J Gastroenterol 38: 798-799, 2003.
8. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP. Resolvin E1- induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci USA 107: 14298-14303, 2010.
9. Compher C, Gilroy R, Pertkiewicz M, Ziegler TR, Ratcliffe SJ, Joly F, Rochling F, Messing B. Maintenance of parenteral nutrition volume reduction, without weight loss, after stopping teduglutide in a subset of patients with short bowel syndrome. J Parenter Enteral Nutr 35: 603-609, 2011.
10. Dahlqvist A. Assay of intestinal disaccharidases. Anal Biochem 22: 99-107, 1968.
11. Dahly EM, Gillingham MB, Guo Z, Murali SG, Nelson DW, Holst JJ, Ney DM. Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. Am J Physiol Gastrointest Liver Physiol 284: G670-G682, 2003.
12. Dahly EM, Guo Z, Ney DM. IGF-I augments resection-induced mucosal hyperplasia by altering enterocyte kinetics. Am J Physiol Regul Integr Comp Physiol 285: R800-R808, 2003.
13. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293: E460-E465, 2007.
14. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131: 589-605, 2006.
15. Estall JL, Drucker DJ. Glucagon-like Peptide-2. Annu Rev Nutr 26: 391-411, 2006.
16. Gillingham MB, Dahly EM, Carey HV, Clark MD, Kritsch KR, Ney DM. Differential jejunal and colonic adaptation due to resection and IGF-I in parenterally fed rats. Am J Physiol Gastrointest Liver Physiol 278: G700-G709, 2000.
17. Gillingham MB, Kritsch KR, Murali SG, Lund PK, Ney DM. Resection upregulates the IGF-I system of parenterally fed rats with jejunocolic anastomosis. Am J Physiol Gastrointest Liver Physiol 281: G1158-G1168, 2001.
18. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130: 150-164, 2006.
19. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125: 136-147, 2003.
20. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21: 73-80, 2000.
21. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60: 902-914, 2011.
22. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut 45: 559-563, 1999.
23. Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009: 616054, 2009. Published online 2009 August 20. doi:10.1155/2009/616054.
24. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagonlike peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54: 1224-1231, 2005.
25. Knott AW, Juno RJ, Jarboe MD, Profitt SA, Erwin CR, Smith EP, Fagin JA, Warner BW. Smooth muscle overexpression of IGF-I induces a novel adaptive response to small bowel resection. Am J Physiol Gastrointest Liver Physiol 287: G562-G570, 2004.
26. Kocoshis SA. Medical management of pediatric intestinal failure. Semin Pediatr Surg 19: 20-26, 2010.
27. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ. Glucagonlike peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res 68: 7897-7904, 2008.
28. Koopmann MC, Chen X, Holst JJ, Ney DM. Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure. Am J Physiol Gastrointest Liver Physiol 299: G1222-G1230, 2010.
29. Koopmann MC, Liu X, Boehler CJ, Murali SG, Holst JJ, Ney DM. Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome. J Parenter Enteral Nutr 33: 629-638, 2009.
30. Koopmann MC, Nelson DW, Murali SG, Liu X, Brownfield MS, Holst JJ, Ney DM. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. J Parenter Enteral Nutr 32: 254-265, 2008.
31. Kripke SA, De Paula JA, Berman JM, Fox AD, Rombeau JL, Settle RG. Experimental short-bowel syndrome: effect of an elemental diet supplemented with short-chain triglycerides. Am J Clin Nutr 53: 954-962, 1991.
32. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 102: 344-352, 1980.
33. Le HD, Fallon EM, de Meijer VE, Malkan AD, Puder M, Gura KM. Innovative parenteral and enteral nutrition therapy for intestinal failure. Semin Pediatr Surg 19: 27-34, 2010.
34. Lee SJ, Lee J, Li KK, Holland D, Maughan H, Guttman DS, Yusta B, Drucker DJ. Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology 153: 1141-1151, 2012.
35. Leen JL, Izzo A, Upadhyay C, Rowland KJ, Dube PE, Gu S, Heximer SP, Rhodes CJ, Storm DR, Lund PK, Brubaker PL. Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology 152: 436-446, 2011.
36. Lei NY, Ma G, Zupekan T, Stark R, Puder M, Dunn JC. Controlled release of vascular endothelial growth factor enhances intestinal adaptation in rats with extensive small intestinal resection. Surgery 150: 186-190, 2011.
37. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 295: R1794-R1802, 2008.
38. Liu X, Murali SG, Holst JJ, Ney DM. Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats. Am J Physiol Regul Integr Comp Physiol 297: R1554-R1562, 2009.
39. Liu X, Nelson DW, Holst JJ, Ney DM. Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. Am J Clin Nutr 84: 1142-1150, 2006.
40. Longshore SW, Wakeman D, McMellen M, Warner BW. Bowel resection induced intestinal adaptation: progress from bench to bedside. Minerva Pediatr 61: 239-251, 2009.
41. Mardini HE, de Villiers WJ. Teduglutide in intestinal adaptation and repair: light at the end of the tunnel. Expert Opin Investig Drugs 17: 945-951, 2008.
42. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 286: G964-G972, 2004.
43. Murali SG, Brinkman AS, Solverson PM, Pun W, Pintar JE, Ney DM. Exogenous GLP-2 and IGF-I induce a differential intestinal response in IGF binding protein-3 and -5 double knockout mice. Am J Physiol Gastrointest Liver Physiol 302: G794-G804, 2012.
44. Murali SG, Liu X, Nelson DW, Hull AK, Grahn M, Clayton MK, Pintar JE, Ney DM. Intestinotrophic effects of exogenous IGF-I are not diminished in IGF binding protein-5 knockout mice. Am J Physiol Regul Integr Comp Physiol 292: R2144-R2150, 2007.
45. Murali SG, Nelson DW, Draxler AK, Liu X, Ney DM. Insulin-like growth factor-I (IGF-I) attenuates jejunal atrophy in association with increased expression of IGF-I binding protein-5 in parenterally fed mice. J Nutr 135: 2553-2559, 2005.
46. Nehra D, Fallon EM, Puder M. The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg Clin North Am 91: 543-563, 2011.
47. Nelson DW, Murali SG, Liu X, Koopmann MC, Holst JJ, Ney DM. Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 294: R1175-R1184, 2008.
48. Rangel SJ, Calkins CM, Cowles RA, Barnhart DC, Huang EY, Abdullah F, Arca MJ, Teitelbaum DH. Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg 47: 225-240, 2012.
49. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 301: G1-G8, 2011.
50. Rowland KJ, Brubaker PL. Life in the crypt: a role for glucagon-like peptide-2? Mol Cell Endocrinol 288: 63-70, 2008.
51. Scarpello JH, Cary BA, Sladen GE. Effects of ileal and caecal resection on the colon of the rat. Clin Sci Mol Med 54: 241-249, 1978.
52. Spencer AU, Neaga A, West B, Safran J, Brown P, Btaiche I, Kuzma-O'Reilly B, Teitelbaum DH. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 242: 403-412, 2005.
53. Stephens J, Stoll B, Cottrell J, Chang X, Helmrath M, Burrin DG. Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets. Am J Physiol Regul Integr Comp Physiol 290: R283-R289, 2006.
54. Tavares W, Drucker DJ, Brubaker PL. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 278: E134-E139, 2000.
55. Teitelbaum DH, Tracy T. Parenteral nutrition-associated cholestasis. Semin Pediatr Surg 10: 72-80, 2001.
56. Thompson JS, Rochling FA, Weseman RA, Mercer DF. Current management of short bowel syndrome. Curr Probl Surg 49: 52-115, 2012.
57. Trivedi S, Wiber SC, El-Zimaity HM, Brubaker PL. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 302: G840-G849, 2012.
58. Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 12: 526-532, 2009.
59. Wessel JJ, Kocoshis SA. Nutritional management of infants with short bowel syndrome. Semin Perinatol 31: 104-111, 2007.
60. Yusta B, Holland D, Koehler JA, Maziarz M, Estall JL, Higgins R, Drucker DJ. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology 137: 986-996, 2009.